The Educated Pharmacist: No More Sugar Coating -- An Interactive Case Workshop for Pinpointing Barriers to Optimal Insulin Use

Program Description

Successful management of type 2 diabetes (T2D) is often impacted by patient-related challenges and barriers, including injection burden and fear of hypoglycemia, that contribute to suboptimal medication-taking behavior or treatment and clinical inertia. However, these challenges in clinical practice are often underrecognized, as more than 75% of people living with T2D who are receiving insulin therapy remain above the American Diabetes Association’s recommended target glycemic goal of HbA1c less than 7%. This session includes an expert faculty panel and a highly interactive workshop format that will guide learners through a collaborative patient case and focused discussions. The case discussion offers a realistic scenario to practice timely therapeutic intervention and discuss guideline-aligned insulin modification plans. Pharmacists will gain the necessary skills to identify people living with T2D experiencing suboptimal glycemic outcomes despite insulin therapy, recognize challenges associated with suboptimal medication-taking behavior and complex regimens, and apply best practices in insulin therapy modification and counseling. This activity will also explore the potential role of emerging once-weekly insulin therapies in simplifying treatment regimens. Shared decision-making strategies and patient-centered communication will be highlighted to support necessary insulin therapy adjustments to overcome therapeutic inertia. Upon completion, all attendees will receive access to a "Train the Trainer" toolkit, enabling them to help support additional pharmacists within their own clinical practices.

Target audience: Community Pharmacist, Health System Pharmacist, Ambulatory Care Pharmacist
Type of activity: Application
Release date: April 10, 2026
Expiration date: April 10, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate how specific patient-related factors, such as insulin injection burden, fear of hypoglycemia, and medication-taking behavior, contribute to clinical and therapeutic inertia in type 2 diabetes management
• Construct insulin modification plans based on individualized glycemic goals and guidelines to facilitate therapy adjustment and uptake of emerging once-weekly formulations
• Use counseling techniques and patient-centered communication strategies to support insulin medication-taking behavior and individualized diabetes management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-051-H01-P. The activity is available for CE credit through April 10, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: MiniMed, Tandem

Speakers Bureau: Abbott, CeQur, Dexcom, Insulet, Lilly, Novo Nordisk, Sanofi, Sequel Pharma

Wendy Mobley-Bukstein, PharmD, BCACP, CDCES, CHWC, NASM-CPT, FAPhA, FADCES, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Abbott Diabetes Care

Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM, has the following relevant financial relationships with ineligible companies to disclose:

Consultant (advisory board): Insulet, Lilly

Speakers Bureau: Cequr, Insulet

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD, RPh; Katie Naspo; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms